Severe Psoriasis - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017

  • ID: 4038198
  • Drug Pipelines
  • Region: Global
  • 120 pages
  • DelveInsight
1 of 3
Severe Psoriasis - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017 provides comprehensive insights about marketed and Phase III products for the Severe Psoriasis. The report includes information of marketed products including their product description, patent details, forecasted sales till 2020 & API manufacturer details by country. It also provides a comprehensive understanding of the emerging Phase III therapies for Severe Psoriasis which can turn out to be future prospective competitors for the marketed products. It will also put light on the current market trends.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts.

Secondary information and data has been collected from various printable and non-printable sources like search engines, news websites, government websites, trade journals, white papers, magazines, trade associations, books, industry portals, industry associations and available databases.

Scope:
  • A review of the marketed products for Severe Psoriasis including their description, route of synthesis, regulatory milestones, forecasted sales estimates till 2020 and API manufacturer details.
  • Patent information coverage of the marketed products including the patent number, holder, grant and patent expiry details
  • API manufacturers for the marketed products with location details
  • Emerging Phase III product profiles for Severe Psoriasis including product description, developmental activities, licensors & collaborators and chemical information
Reasons to Buy:
  • API intelligence for marketed drugs for the indication and gaining insights of API manufacturers
  • Evaluate the marketing status and patent details of products to exploit opportunities for generic drug development
  • Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry details and exclusivity with respect to the indication
  • Establish a comprehensive understanding of the emerging Phase III products which can be future competitors in this space
Note: Please allow up to 48 hours for delivery of this report after payment has been made.
READ MORE
Note: Product cover images may vary from those shown
2 of 3
Report Introduction
Overview
Comparative Analysis of Marketed and Emerging Products
Marketed Therapies
Drug Name: Company Name
  • Product Description
  • Regulatory Milestones
  • Drug Historical Annual Global Sales
  • Drug Forecasted Annual Global Sales
  • Global Active Pharmaceutical Manufacturers for drug
  • Patent Details
Emerging Therapies - Phase III
Drug Name: Company Name
  • Product Description
  • Research and Development
  • Other Development Activities
Appendix
Methodology
Consulting Services
Disclaimer
About

List of Tables
Table 1: List of Marketed and Emerging Products
Table 2: Drug Annual Global Sales from 2011-2016 (in million USD)
Table 3: Drug Annual Global Sales from 2017-2020 (in million USD)
Table 4: Active Pharmaceutical Manufacturers by Country
Table 5: Active Pharmaceutical Manufacturers by Region

List of Figures
Figure 1: Comparative Analysis of Marketed and Emerging Products
Figure 2: Drug Annual Global Sales from 2011-2016 (in million USD)
Figure 3: Drug Annual Global Sales from 2017-2020 (in million USD)
Figure 4: Active Pharmaceutical Manufacturers by Country
Figure 5: Active Pharmaceutical Manufacturers by Region
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll